Biogen Inc. $BIIB Shares Purchased by MUFG Securities EMEA plc

MUFG Securities EMEA plc boosted its position in Biogen Inc. (NASDAQ:BIIB) by 114.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,017 shares of the biotechnology company’s stock after purchasing an additional 3,211 shares during the quarter. MUFG Securities EMEA plc’s holdings in Biogen were worth $1,059,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Rothschild Investment LLC increased its stake in shares of Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 56 shares during the last quarter. Advisory Services Network LLC increased its stake in shares of Biogen by 3.9% during the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 68 shares during the last quarter. Davis Investment Partners LLC increased its stake in shares of Biogen by 1.7% during the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 71 shares during the last quarter. Optas LLC increased its stake in shares of Biogen by 4.5% during the 4th quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 73 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Biogen by 8.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 89 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Down 1.8%

Shares of NASDAQ:BIIB opened at $188.83 on Wednesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97. The stock has a market capitalization of $27.88 billion, a P/E ratio of 20.26, a PEG ratio of 1.69 and a beta of 0.20. The stock has a 50-day simple moving average of $186.83 and a 200-day simple moving average of $182.63.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the business earned $3.02 EPS. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities analysts forecast that Biogen Inc. will post 14.18 earnings per share for the current year.

Analysts Set New Price Targets

BIIB has been the subject of a number of research analyst reports. UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and upped their price objective for the company from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Canaccord Genuity Group upped their price objective on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. Royal Bank Of Canada upped their price objective on shares of Biogen from $222.00 to $227.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. The Goldman Sachs Group upped their price objective on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Finally, Barclays initiated coverage on shares of Biogen in a research note on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $215.81.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.